FrostPharma wins two national tenders in Norway

FrostPharma is proud and pleased to announce that the company has been successful in the tender bidding process in Norway. The company has been notified of winning two national tender contracts in two different therapeutic areas, starting Feb 1, 2022 and running for two years with option to prolong another two years. This means that the health care providers and patients eligible for these specific treatments will have access to our value-added products throughout the tender contract period in Norway. The therapeutic areas in scope for these two treatments are sedation and anti-thrombotic treatment.

FrostPharma strengthens product portfolio with deal of 5 additional hospital pharmaceuticals

FrostPharma has entered an agreement with STEROP, bringing 5 additional products to the current FrostPharma portfolio. The deal encompasses commercial rights, including distribution and market authorization rights for the included products.

“FrostPharma has showed a very strong development since the start in 2017 and we have continuously reinvested the profits to build the portfolio with value-added products, allowing us to bring beneficial treatment options across multiple disease areas to our markets. With this agreement we will further strengthen the long-term outlook for FrostPharma’s future growth in all the Nordic countries.”, says CEO Cecilia Bröms-Thell.

The expected sales for the products included in the agreement with STEROP will contribute significantly to the top-line growth of FrostPharma already in the near-term perspective.

About FrostPharma AB:

FrostPharma is an entrepreneurial Swedish pharmaceutical company specializing in the commercialization of value-added products.

Since the start in 2017, FrostPharma has successfully commercialized a broad range of products across multiple disease areas, throughout the Nordic countries and beyond. The key to our success is using our extensive in-house commercialization competence to match specific patient and health care needs with relevant products.

About STEROP:

STEROP is a Belgian pharmaceutical group with the ambition to be a global leading player in the field of essential medicines and innovative products.

ExCEEd Orphan s.r.o. announces joining Your Pharma Partner in Europe network as of May 1, 2021

• May 1, 2021

ExCEEd Orphan s.r.o. (www.exceedorphan.com), are a Czech-based full business solution provider for Biotechnology and Pharmaceutical companies who are launching their products in Central & Eastern Europe. They proudly announce joining the exclusive network of Your Pharma Partner in Europe (www.yourpharmapartner.eu) as of May 1st, 2021. This exclusive network was established in 2012 by two founding partner companies FrostPharma AB based in Sweden (www.frostpharma.com and TwinPharma B.V. based in Netherlands (www.twinpharma.com). With the addition of 14 countries in Central & Eastern Europe covered by ExCEEd Orphan, this network is now able to provide services and deliver innovative treatments to patients in 25 European countries that have a population totaling 180 million. All three partner companies agreed to offer jointly their services to Biotechnology and Pharmaceutical companies looking for partners in Nordics & Baltics, BeNeLux and CEE regions: however, they remain as independent contracting, financing, and business operations.

Jiri Hermanek, CEO and Founding Partner of ExCEEd Orphan s.r.o comments: “We are very proud to join such an exclusive network covering 40% of the European population! We are looking forward to working in partnership with Frost Pharma AB and TwinPharma B.V. to bring innovative medicines to patients in CEE countries.”

Cecilia Bröms-Thell, CEO of FrostPharma AB comments: “We at FrostPharma welcome ExCEEd Orphan s.r.o. to our joint partnership network! Their expertise and knowledge of marketing and sales in the CEE region will enable us to extend our offerings to additional clients interested to launch their products in this important territory.”

Gert van Alewijk, Founding Partner of TwinPharma B.V. adds: “We at TwinPharma are excited and proud to have ExCEEd Orphan s.r.o. as a new partner in our network. By joining us, we expand our territory to such an extent that we become an even more attractive partner for companies that want to introduce their pharmaceuticals in 25 European countries outside the traditional Big 5.

ExCEEd Orphan s.r.o. was founded in 2018 by 5 rare disease experts from multiple countries. The company is focusing on innovative treatments for rare diseases and has extensive experience in launching innovative medicines in this field. The portfolio of ExCEEd Orphan s.r.o. includes products in therapeutic areas such as hematology, neurology, immunology, and metabolic diseases.

FrostPharma AB is an entrepreneurial Swedish pharmaceutical company specialized in commercialization of products creating value. Since the start in 2017, FrostPharma has successfully commercialized a broad range of products across multiple disease areas, covering all Nordic countries and beyond. Key to success is the ability to match specific patient- and healthcare needs with relevant products in relation to our extensive in-house commercialization competence.

TwinPharma B.V. was founded in 2006 by two experienced Pharma industry professionals Gert van Alewijk and Bauke Buwalda in Netherlands. With TwinPharma, they want to contribute to improving healthcare by making available medicines that were previously not available in the region. The company is focusing on innovative treatments and is currently active in several disease areas such as immunology, hepatology, organ transplant and urology.

For further information, please refer to:

www.yourpharmapartner.eu www.exceedorphan.com

www.frostpharma.com

www.twinpharma.com